Fig. 1: Metformin reduced the m6A level via decreasing METTL3 expression.
From: Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m6A/p21 pathway
A–C Metformin inhibited the growth of SUM-1315, MCF-7, and BT-474 cells in both dose-dependent and time-dependent manners. D Dot-blot assay showed that metformin decreased the m6A level in SUM-1315, MCF-7, and BT-474 cells. MB, methylene blue staining (loading control). E, F RNA expression changes of the 5 key m6A methyltransferases and demethylases including METTL3, METTL14, WTAP, FTO, and ALKBH5 after the treatment of metformin in SUM-1315 and MCF-7 cells. G, H Metformin decreased the mRNA and protein expression of METTL3 in a dose-dependent manner. The relative RNA level was calculated by the 2−ΔΔCt method and normalized based on β-actin. The average mRNA level of genes mentioned above in the metformin untreated group was set as 1. Data represented the mean ± SD, *p < 0.05, **p < 0.01 vs metformin-untreated group.
